Q&A with Stuart E. Needleman, Aptuit - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Stuart E. Needleman, Aptuit
A Q&A with Stuart E. Needleman, President and Chief Operating Officer of Aptuit, on recent industry trends.

Pharmaceutical Technology
Volume 37, Issue 5, pp. 84

PharmTech:
Can you explain Aptuit's capabilities and how it integrates its services across its network?


Stuart E. Needleman
Needleman:
We have API chemistry manufacturing and a business that does solid-state analysis (i.e., the bridge between the formula API manufacturer and formulation development). We have a sterile fill-finish business in the early phase of Phase I, proof-of-concept capabilities, small-dose, as well as a large-scale internal capability, and an R&D engine that we acquired from GlaxoSmithKline in Verona, Italy, which includes integrated drug development, discovery through to dosage form, including toxicology and chemistry.

PharmTech:
What are some of the key trends influencing pharmaceutical outsourcing overall, and in the specific sectors of Aptuit services, like formulation, development, and API manufacturing?

Needleman:
There is a restructuring that will continue to go on inside big pharma as they focus on their sites, their facilities, their overheads, and their pipelines. There is some turmoil in the internal pharma R&D; and we want to make sure that we are there to serve those clients as they go through those restructurings and potentially rebalance their portfolio.

We also want to make sure we're following the pipelines of the emerging pharmaceutical companies because, again, innovation continues to come from the smaller companies. We want to make sure we meet the needs of where we see the industry going whether it's therapeutic areas, or whether it's going to be much more focused on oncology in the high potency areas. We want to make sure that we're meeting the market needs or the market demand. We also want to understand where the market is heading and be able to offer services, technologies, and capabilities to meet those needs.

For example, if it's going to be in the prefilled syringe area, we want to make sure we're making investments in that. We have created a scientific advisory board internally made up of some of our leading scientists around our network to discuss the future direction of technology, market, and commercial needs, so we're prepared to evaluate and build strategies around our clients' needs.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here